Evidence map›Paper›PMID 39542970›Full record

ArticleEJNMMI research2024

Primary mesenchymal tumors of the prostate:

Zihao Tao, Yongkang Qiu, Zhao Chen, Wenpeng Huang, Lele Song, Aixiang Wang, Xuesong Li, Lei Kang

Abstract read
In one paragraph

Article in EJNMMI research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zihao TaoDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, China.
Yongkang QiuDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, China.
Zhao ChenDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, China.
Wenpeng HuangDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, China.
Lele SongDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, China.
Aixiang WangDepartment of Urology Pathology, Peking University First Hospital, Beijing, 100034, China.
Xuesong LiDepartment of Urology, Institute of Urology, Peking University First Hospital, Peking University, National Urological Cancer Center, Beijing, 100034, China. pineneedle@sina.com.
Lei KangDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, China. kanglei@bjmu.edu.cn.ORCID http://orcid.org/0000-0001-8729-4547

Funding

Beijing Science Foundation for Distinguished Young Scholars JQ21025Interdisciplinary Research Project of Peking University First Hospital 2023IR17National Natural Science Foundation of China 82171970
6 · The paper itself

Abstract

backgroundPrimary mesenchymal tumors of the prostate are very rare, and there is no systematic report on fluorine-18-fluorodeoxyglucose positron emission tomography (

resultsWe included 13 patients with pathologically confirmed mesenchymal neoplasms of the prostate. The location, size, maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total glycolysis of the lesion (TLG), pathologic findings, and available imaging study of the tumors were reviewed. Of the 13 patients (median age, 38 years; ranged from 13 to 74 years), the mean size of the tumors was 8.8 cm in diameter ranged from 5 to 16.1 cm. SUVmax ranged from 3.1 to 17.6 (mean 9.5), MTV ranged from 4.9 to 398 cm

conclusionsMesenchymal tumors of the prostate revealed large sizes and high SUVmax, MTV and TLG levels on

Identifiers

PMID39542970
PMCPMC11564716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.